Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19919650 | 1.00 | TERT (0.43) | TERTUSP2TSHRDPP7DPP4 | |
| SCHEMBL10448381 | 0.89 | DPP7 (0.51) | TERTUSP2TSHRDPP7RRM1 | |
| SCHEMBL3666708 | 0.86 | USP2 (0.47) | TERTUSP2TSHRDPP7DPP4 | |
| SCHEMBL14593722 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL10548785 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL10551440 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL5867316 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL5867315 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL10551446 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL10548780 | 0.85 | DPP7 (0.57) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | TERT 504/4885USP2 4160/4885TSHR 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.